CD274 and neoplasm: Beyond traditional H&E staining, pathomics encompasses molecular markers associated with drug response including ER, PR, HER2, Ki67, and PD‐L1, as well as related genomic and proteomic datasets that reflect tumor sensitivity to existing therapies.